PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- The primary objective of the study is to demonstrate the superiority of telithromycin
over azithromycin and over cefuroxime axetil in the reduction of Streptococcus
pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure
(TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit
1).
Secondary Objectives:
The secondary objectives of the study are:
- To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime
axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit
in patients with Sp detected in sputum specimen at the start of the study (Visit 1);
- To compare the clinical cure rates achieved by each treatment group in the penicillin or
erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp
(SSp) population at the End of Therapy (EOT) and Test of Cure visits;
- To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of
Therapy visit on the presence of Streptococcus pneumoniae strains resistant to
beta-lactams or macrolides in the sputum of patients with Sp detected at the start of
the study (Visit 1);
- To compare the clinical efficacy at the End of Therapy visit and safety at the Test of
Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global"
randomized population.